It is now very clear that the global pharmaceutical industry is in a period of significant change, and with it the environment for innovative product launch. Molecular innovation is being supplemented, and in some instances could be replaced, by other forms of innovation, including highly individualised and procedure-like cell and gene therapies, prescription digital therapeutics, or innovation on existing, off-patent molecules.
Launch Excellence VI – IQVIA